IBIO — Stock Film
STOCK FILMSCENE 1/11IBIO · $1.43
Stock Expert AI presents
IBIO
iBio, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
iBio, Inc. A quick introduction.

On the stock market since 2008, it operates in the world of health and science. It has 20 employees. Now — the numbers.

on the stock market since 2008
20 employees
$22.6M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $47.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales have been shrinking.

An average decline of 36% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$2.4M
2021
$1.9M
2022
$0
2023
$225K
2024
$400K
2025
In the vault right now:
$0
DEBT: $3.5M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
8
very weak

Clearly below the class average.

FINANCIAL STRENGTH
40
weak

Clearly below the class average.

VALUATION
63
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
53
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
31
very weak

Clearly below the class average.

WORTH WATCHING

Business Quality: Profit power and business quality trail similar companies in the sector.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Executives aren’t buying3/10
Costs eat into the margin4/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Sales are holding up

The company sells $400K a year; the problem isn’t sales — it’s costs running above that number.

2
THE BRIGHT SIDE · 2/2
Analysts’ target sits above today’s price

The average analyst price target is $5.00250% above today’s price.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $18.4M against $400K in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, IBIO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: IBIO is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film